Literature DB >> 28815653

Reply to Letter: The Use of IC50 for Potency and MTD as Objective in Study BIA 10-2474, by Mattheus van Iersel, MD.

Philip Chaikin1.   

Abstract

Entities:  

Keywords:  Biomarkers; Central Nervous System (CNS); Clinical Pharmacology (CPH); Clinical Research (CRE); Pharmacodynamics (PDY)

Mesh：

Substances：

Year:  2017        PMID： 28815653     DOI： 10.1002/jcph.1000

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  2 in total

Review 1.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

2.  Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.

Authors:  José-Francisco Rocha; Ana Santos; Helena Gama; Paul Moser; Amílcar Falcão; Peter Pressman; A Wallace Hayes; Patricio Soares-da-Silva
Journal:  Clin Pharmacol Ther       Date:  2021-06-24       Impact factor: 6.903
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.